MedPath

Quinidine

Generic Name
Quinidine
Brand Names
Nuedexta
Drug Type
Small Molecule
Chemical Formula
C20H24N2O2
CAS Number
56-54-2
Unique Ingredient Identifier
ITX08688JL
Background

Quinidine is a D-isomer of quinine present in the bark of the Cinchona tree and similar plant species. This alkaloid was first described in 1848 and has a long history as an antiarrhythmic medication. Quinidine is considered the first antiarrhythmic drug (class Ia) and is moderately efficacious in the acute conversion of atrial fibrillation to normal sinus rhythm. It prolongs cellular action potential by blocking sodium and potassium currents. A phenomenon known as “quinidine syncope” was first described in the 1950s, characterized by syncopal attacks and ventricular fibrillation in patients treated with this drug. Due to its side effects and increased risk of mortality, the use of quinidine was reduced over the next few decades. However, it continues to be used in the treatment of Brugada syndrome, short QT syndrome and idiopathic ventricular fibrillation.

Indication

Quinidine is indicated for the management and prophylactic therapy of atrial fibrillation/flutter, as well as the suppression of recurrent documented ventricular arrhythmias. It is also used in the treatment of Brugada syndrome, short QT syndrome and idiopathic ventricular fibrillation..

Associated Conditions
Atrial Fibrillation or Flutter, Malaria caused by Plasmodium falciparum, Pseudobulbar Affect (PBA), Ventricular Arrhythmia

ALS Drug Development Gains Momentum with New Research Approaches and Industry Investment

• Recent scientific breakthroughs and technological advances have reinvigorated ALS drug development, with over 60 clinical trials currently recruiting participants and increased investment from major pharmaceutical companies. • Amylyx Pharmaceuticals' AMX0035 shows promise in clinical trials, demonstrating both functional benefit and survival advantage of approximately 6.5 months compared to placebo. • Genetic research has identified dozens of ALS-associated genes, leading to targeted therapies like Biogen's tofersen, though challenges remain in treating the 90% of cases with unknown causes.
© Copyright 2025. All Rights Reserved by MedPath